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 Mushroom preparations are used widely in Asia as complements to conventional cancer 
therapies, and have been used so for many years.  In the last ten years they have become more widely 
available in the western world. Various medications derived from different mushrooms, especially 
Coriolus, Shitake, Reishi and Maitake mushrooms, have been studied.  Two other combination agents, 
active hexose correlated compound (AHCC), and MGN-3 deserve mention, particularly because of their 
widespread use. 
Physiological Effects 
 
 Mushrooms are commonly thought of as immunopotentiating agents.  Their effects, however, 
extend far wider than only the immunological system. 
 
 Their effects on the immune system are thought to be mediated through B-D glucan linkages in 
their chemical structure.  These are monosaccharide polymers.  These monosaccharides can also be 
linked to proteins, where they are then termed proteoglycans.  Numerous immunologically related 
activites have been confirmed with the use of mushroom preparations, including dendritic cell 
maturation and activation, macrophage and phagocytic activation, NK cell activation, improvement of 
the CD4/CD8 and Th1/Th2 ratios, and increased production of various cytokines, including interleukins 
1, 2, 6, 8, interferons and tumor necrosis factor (1,2,3). These could all be beneficial in patients with 
malignancies 
 
In addition to their direct immune effects, mushroom preparations have been shown to have other effects 
that could be clinically beneficial for cancer patients.  These include inhibiting important transcription 
factors that are antiapoptotic, such as NFkB, AP-1, and urokinase plasminogen activator (4,5,6). 
Mushroom preparations have been shown to have antioxidant properties, have been able to mimic the 
free scavenging effects of superoxide dismutase and can increase glutathione peroxidase activity (7,8,9). 
Other activites include the decreasing of myelosuppression associated with chemotherapy in a murine 
model, increasing hematopoesis (10), and the overcoming of resistance of tumor cells to complement 
mediated cytotoxicity (11). Monoclonal antibodies work through various mechanisms, including having 
direct tumor cytotoxic effects, through the activation and enabling of NK cells, and through complement 
mediated cytotoxicity.  Studies have suggested that the combination of a B-glucan substance, such as 
found in mushrooms, can enhance the effect of monoclonal antibodies .  Cheung has studied the effect 
of combining B-glucans with monoclonal antibodies in numerous tumor cell lines and has found a very 
significant enhancement of cytotoxicity (12,13). This appears to occur by overcoming tumor cell 
resistance to opsonization with the C3. With the burgeoning interest and increasing use of monoclonal 
antibodies, this property of mushrooms has potential importance. 
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Mushroom preparations, in addition to being investigated in cell culture, in vitro and animal 
studies, have been relatively widely studied in humans (compared to other integrative treatment 
modalities), including randomized clinical studies, with promising results.  This is true especially for the 
preparations from Coriolus mushrooms, known as PSK or Krestin, and PSP. Most of the following 
discussion will be centered on these medications. 
 
Clinical Trials with Coriolus Preparations 
 
Medicines derived from the Coriolus Versicolor mushroom have been  studied in patients with 
colorectal malignancies. Ohwada studied patients with  Stage II or III colorectal cancer, comparing a 
group treated with surgery and chemotherapy versus a group which also received PSK produced from 
Coriolus.  After three years they found a mild benefit in disease free survival (80.6 vs 68.7 p=0.02), and 
overall survival (87.3 vs 80.6 p= 0.024) in the PSK group. In stage III patients the three-year overall 
survival was improved  (83 vs 59.3 p= 0.02). The treatment group also showed a decrease in distant 
metastases (0.05), particularly to the lung (0.01). (14) 
 
Ito studied patients with Dukes C colorectal tumors, comparing 440 patients treated with either 5 
FU and PSK, or with 5 FU alone.  He found a statistical difference in cancer related deaths ( 49 vs. 37, 
p= 0.19) in the treated group (15).Other studies (16, 17) have supported these positive findings. 
 
PSK has been extensively studied in gastric cancer, which is a very common malignancy in 
Asian countries. Kaibara compared a group with stage IV gastric cancer, comparing conventional chemo 
and surgical treatment with or without PSK.  Two year survival was improved (34 vs. 15% p<0.05)(18). 
Numerous studies by the group of Kodama, Kano et al. confirmed significant benefit from the addition 
of PSK to the usual treatment regimens (19,20). A study by Nakazoto, published in the Lancet, showed a 
slight benefit in 5 year disease free and survival rate (70.7 vs. 59.4% p=0.047, 73 vs. 60% p=0.044), in 
the group treated with standard treatment and PSK versus the group without PSK(21). 
 
 Ogoshi compared patients with esophageal cancer treated with conventional treatment with or 
without chemotherapy, and found a non-statistically significant trend towards improvement in 5-year 
survival. They found that the improved survival was noted especially in patients with the presence of 
high levels of immunosuppressive substances sialic acid and alpha i-antichymotrypsin (22,23). 
Hayakawa compared patients with non-small cell lung cancer who were treated with radiation 
therapy with or without PSK.  Five year survival rates were significantly improved in the PSK group in 
stages I, II and III (39 vs 17, 26 vs 8%)(24). 
 
Studies have also been reported in breast cancer and leukemias (see ref 1 for summary). 
 
Studies with Other Mushroom Preparations 
 
While the bulk of research has been with Coriolus derived medications, some provocative studies 
have looked at AHCC and MGN-3. MGN-3, which is a rice bran compound that is modified by 
mushroom enzymes, has shown very impressive results regarding augmentation of NK activity. Most of 
the studies have been done by a single group, so caution should be applied in the reproducibility of this 
data. The compound AHCC has been studied in numerous situations.  A study in patients with 
hepatocellular carcinoma showed significant benefit when AHCC was employed after surgical resection 
(25).  AHCC has been combined with genistein in a product called Genistein Combined Polysaccharide 
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(GCP). The presence of the isoflavone genistein might be helpful in patients with prostate cancer, both 
because of its estrogen like effects, as well as effects on protein kinase C. A provocative case report 
discussed the use of this product in a patient with prostate cancer. This patient had biopsy proven 
prostate cancer with a PSA of 19.7.  He was treated for six weeks with GCP prior to radical 
prostatectomy.  The PSA decreased to 4.2 and the surgical specimen showed no evidence of tumor (26). 
 
Other mushroom preparations are of interest and have been studied in preliminary ways.  
Maitake mushrooms, particularly the D fraction, have been studied in animals and in vitro (27,28), 
showing results on relevant aspects of the immune system.  Kodama used Maitake preparations, without 
chemotherapy, in patients with Stage IV tumors in different sites (lung, liver, breast), and found both 
laboratory and clinical evidence of improvement, including some patients with radiological evidence of 
tumor shrinkage and regression (29). Sliva (30,31) has performed a series of interesting experiments 
with Reishi mushrooms, showing beneficial effects on transcription factors as well as inhibiting 
migration of highly invasive prostate and breast cancer cells. 
 
When patients are administered chemotherapy, common effects include immunosuppression, as 
well as an augmented production of transcription factors, such as NFkB and AP-1, which stimulate 
tumor growth and chemoresistance by various mechanisms.  As noted above, mushroom preparations 
can potentially alleviate the immunosuppression, myelosuppression and transcription factor production 
that occurs in patients undergoing chemotherapy.  Therefore their use alongside conventional 
chemotherapy can be expected to be beneficial.  This appears to be confirmed in the numerous studies 
cited above. 
 
Conclusions 
 
 In summary, mushroom preparations have been shown to have a wide range of physiological 
effects which are likely to be beneficial in patients with malignancies. These extend beyond immune 
system stimulation to additional effects on transcription factors, antioxidant effects, and inhibiting 
invasion.  There are also intriguing studies combining their use with monoclonal antibodies.  Clinical 
studies in a diverse range of tumors have shown mild to moderate additive benefits when combined with 
conventional treatment regimens. Although these preparations have been shown to have antioxidant 
effects alongside their other actions, no evidence for interference with chemotherapy or radiation 
therapy exists.  Indeed the studies suggest the opposite; an augmentation of their benefit.  
 
Numerous mushroom preparations are available, including combinations of different 
mushrooms, and products containing isolated B-glucans.  The most widely studied mushrooms are those 
prepared from Coriolus Versicolor, where in addition to cell line, animal, in vitro and in vivo studies, 
numerous randomized clinical studies have been completed.  Other mushrooms, especially Maitake and 
Reishi, have a more limited evidence base.  Two unusual products, AHCC and MGN-3 are used and 
marketed widely, but have an interesting, but clearly smaller evidence base.  Some products contain 
combinations of different mushrooms.  Individual mushrooms have overlapping, but unique 
compositions and properties.  These combination products might show synergistic actions, but have not 
been studied. The side effect profile of these preparations is minimal. Costs at the present time are not, 
however, insubstantial.  A one-month course can cost between $100-200. 
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